AU2022233762A1 - Method of treating diseases using gremlin1 antagonists - Google Patents

Method of treating diseases using gremlin1 antagonists Download PDF

Info

Publication number
AU2022233762A1
AU2022233762A1 AU2022233762A AU2022233762A AU2022233762A1 AU 2022233762 A1 AU2022233762 A1 AU 2022233762A1 AU 2022233762 A AU2022233762 A AU 2022233762A AU 2022233762 A AU2022233762 A AU 2022233762A AU 2022233762 A1 AU2022233762 A1 AU 2022233762A1
Authority
AU
Australia
Prior art keywords
gremlin1
antagonists
treating diseases
diseases
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022233762A
Other languages
English (en)
Inventor
Chaping CHENG
Weiqiang GAO
Xueming Qian
Di SUN
Jinming WANG
He ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Transcenta Therapeutics Co Ltd
Shanghai Jiao Tong University
Original Assignee
Suzhou Transcenta Therapeutics Co Ltd
Shanghai Jiao Tong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Transcenta Therapeutics Co Ltd, Shanghai Jiao Tong University filed Critical Suzhou Transcenta Therapeutics Co Ltd
Publication of AU2022233762A1 publication Critical patent/AU2022233762A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022233762A 2021-03-11 2022-03-11 Method of treating diseases using gremlin1 antagonists Pending AU2022233762A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021080142 2021-03-11
CNPCT/CN2021/080142 2021-03-11
CNPCT/CN2022/076516 2022-02-16
CN2022076516 2022-02-16
PCT/CN2022/080297 WO2022188856A1 (en) 2021-03-11 2022-03-11 Method of treating diseases using gremlin1 antagonists

Publications (1)

Publication Number Publication Date
AU2022233762A1 true AU2022233762A1 (en) 2023-10-05

Family

ID=83226314

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022233762A Pending AU2022233762A1 (en) 2021-03-11 2022-03-11 Method of treating diseases using gremlin1 antagonists

Country Status (11)

Country Link
US (1) US20240190950A1 (https=)
EP (1) EP4304646A4 (https=)
JP (1) JP2024513692A (https=)
KR (1) KR20230156936A (https=)
CN (1) CN116940380A (https=)
AU (1) AU2022233762A1 (https=)
BR (1) BR112023018204A2 (https=)
CA (1) CA3213121A1 (https=)
MX (1) MX2023010594A (https=)
TW (1) TW202300527A (https=)
WO (1) WO2022188856A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022152290A1 (en) * 2021-01-18 2022-07-21 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-gremlin1 antibodies
CN120957750A (zh) * 2023-04-13 2025-11-14 苏州创胜医药集团有限公司 用于治疗癌症的涉及grem1拮抗剂的组合疗法
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用
CN119746060B (zh) * 2025-03-07 2025-09-16 南昌大学第一附属医院 一种树突状细胞疫苗制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2826790B1 (en) * 2012-03-15 2019-02-13 SNU R&DB Foundation Anti-gremlin-1 antibody
EA201591762A1 (ru) * 2013-03-14 2015-12-30 Ридженерон Фармасьютикалз, Инк. Человеческие антитела к grem1
CA3030582A1 (en) * 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds and uses thereof in the treatment of cancers and other medical conditions
GB201621635D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
MX2020013808A (es) * 2018-06-18 2021-05-27 UCB Biopharma SRL Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
WO2022152290A1 (en) * 2021-01-18 2022-07-21 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-gremlin1 antibodies

Also Published As

Publication number Publication date
WO2022188856A1 (en) 2022-09-15
TW202300527A (zh) 2023-01-01
EP4304646A1 (en) 2024-01-17
KR20230156936A (ko) 2023-11-15
CA3213121A1 (en) 2022-09-15
US20240190950A1 (en) 2024-06-13
CN116940380A (zh) 2023-10-24
EP4304646A4 (en) 2025-05-28
JP2024513692A (ja) 2024-03-27
BR112023018204A2 (pt) 2023-10-24
MX2023010594A (es) 2023-09-25

Similar Documents

Publication Publication Date Title
AU2022233762A1 (en) Method of treating diseases using gremlin1 antagonists
EP4114855A4 (en) USE OF ANTI-FAM19A1 ANTAGONISTS TO TREAT CENTRAL NERVOUS SYSTEM DISEASES
HK40083783A (en) Method of treatment using meta-arsenite
EP4103200A4 (en) METHOD OF TREATMENT USING META-ARSENITE
AU2021902405A0 (en) Method of treatment
AU2021900204A0 (en) Method of treatment
HK40096076A (en) Compounds for and methods of treating diseases
EP4168408A4 (en) COMPOUNDS AND METHODS FOR TREATING DISEASES
AU2020900433A0 (en) Method of treatment
AU2020900220A0 (en) Method of Treatment
AU2019900867A0 (en) Compounds for and Methods of Treating Diseases
AU2020903058A0 (en) Compounds for and Methods of Treating Diseases
HK40110508A (en) Methods of treatment using lou064
AU2020902019A0 (en) Compounds for and Methods of Treating Diseases
AU2023903893A0 (en) Method of treatment
AU2023901658A0 (en) Method of Treatment
AU2023901529A0 (en) Method of Treatment
AU2023901341A0 (en) Method of Treatment
AU2023900427A0 (en) Method of treatment
AU2022903003A0 (en) Method of Treatment
AU2022902548A0 (en) Method of treatment
AU2022901083A0 (en) Method of Treatment
HK40109636A (en) Methods of treating neurological diseases
CA3304082A1 (en) Methods of treating mat2a related diseases
HK40085342A (en) Use of anti-fam19a1 antagonists for treating central nervous system diseases